vs
GYRE THERAPEUTICS, INC.（GYRE）与PDF SOLUTIONS INC（PDFS）财务数据对比。点击上方公司名可切换其他公司
PDF SOLUTIONS INC的季度营收约是GYRE THERAPEUTICS, INC.的1.7倍（$62.4M vs $37.2M），PDF SOLUTIONS INC净利率更高（-0.1% vs -3.7%，领先3.6%），GYRE THERAPEUTICS, INC.同比增速更快（33.4% vs 24.6%），PDF SOLUTIONS INC自由现金流更多（$7.5M vs $-5.8M），过去两年PDF SOLUTIONS INC的营收复合增速更高（22.9% vs 17.0%）
GYRE Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性血液系统恶性肿瘤和实体瘤的新型靶向疗法，聚焦精准肿瘤学领域以满足未被满足的患者医疗需求，主要在北美地区开展业务。
PDF Solutions Inc是一家总部位于美国加利福尼亚州圣克拉拉的跨国企业，主营软件业务与工程技术服务，目前在纳斯达克交易所挂牌上市，股票代码为PDFS。
GYRE vs PDFS — 直观对比
营收规模更大
PDFS
是对方的1.7倍
$37.2M
营收增速更快
GYRE
高出8.9%
24.6%
净利率更高
PDFS
高出3.6%
-3.7%
自由现金流更多
PDFS
多$13.3M
$-5.8M
两年增速更快
PDFS
近两年复合增速
17.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $37.2M | $62.4M |
| 净利润 | $-1.4M | $-48.0K |
| 毛利率 | 95.3% | 72.9% |
| 营业利润率 | 0.3% | 5.5% |
| 净利率 | -3.7% | -0.1% |
| 营收同比 | 33.4% | 24.6% |
| 净利润同比 | -340.1% | -108.9% |
| 每股收益（稀释后） | $-0.01 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GYREPDFS
| Q4 25 | $37.2M | $62.4M | ||
| Q3 25 | $30.6M | $57.1M | ||
| Q2 25 | $26.8M | $51.7M | ||
| Q1 25 | $22.1M | $47.8M | ||
| Q4 24 | $27.9M | $50.1M | ||
| Q3 24 | $25.5M | $46.4M | ||
| Q2 24 | $25.2M | $41.7M | ||
| Q1 24 | $27.2M | $41.3M |
净利润GYREPDFS
| Q4 25 | $-1.4M | $-48.0K | ||
| Q3 25 | $5.9M | $1.3M | ||
| Q2 25 | $1.6M | $1.1M | ||
| Q1 25 | $3.7M | $-3.0M | ||
| Q4 24 | $569.0K | $539.0K | ||
| Q3 24 | $2.9M | $2.2M | ||
| Q2 24 | $4.5M | $1.7M | ||
| Q1 24 | $9.9M | $-393.0K |
毛利率GYREPDFS
| Q4 25 | 95.3% | 72.9% | ||
| Q3 25 | 94.7% | 72.3% | ||
| Q2 25 | 95.7% | 71.2% | ||
| Q1 25 | 95.9% | 72.9% | ||
| Q4 24 | 95.8% | 68.3% | ||
| Q3 24 | 96.2% | 73.1% | ||
| Q2 24 | 96.9% | 70.6% | ||
| Q1 24 | 96.4% | 67.3% |
营业利润率GYREPDFS
| Q4 25 | 0.3% | 5.5% | ||
| Q3 25 | 22.7% | 8.5% | ||
| Q2 25 | 8.1% | 2.2% | ||
| Q1 25 | 10.3% | -7.4% | ||
| Q4 24 | 2.4% | 1.0% | ||
| Q3 24 | 16.6% | 4.6% | ||
| Q2 24 | 12.7% | 0.6% | ||
| Q1 24 | 29.7% | -4.7% |
净利率GYREPDFS
| Q4 25 | -3.7% | -0.1% | ||
| Q3 25 | 19.4% | 2.3% | ||
| Q2 25 | 5.9% | 2.2% | ||
| Q1 25 | 16.9% | -6.3% | ||
| Q4 24 | 2.0% | 1.1% | ||
| Q3 24 | 11.2% | 4.8% | ||
| Q2 24 | 18.0% | 4.1% | ||
| Q1 24 | 36.6% | -1.0% |
每股收益（稀释后）GYREPDFS
| Q4 25 | $-0.01 | $0.00 | ||
| Q3 25 | $0.03 | $0.03 | ||
| Q2 25 | $0.00 | $0.03 | ||
| Q1 25 | $0.00 | $-0.08 | ||
| Q4 24 | $0.00 | $0.01 | ||
| Q3 24 | $0.01 | $0.06 | ||
| Q2 24 | $0.01 | $0.04 | ||
| Q1 24 | $0.03 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $52.4M | $42.2M |
| 总债务越低越好 | — | $67.0M |
| 股东权益账面价值 | $106.0M | $271.0M |
| 总资产 | $166.1M | $418.7M |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资GYREPDFS
| Q4 25 | $52.4M | $42.2M | ||
| Q3 25 | $60.0M | $35.9M | ||
| Q2 25 | $54.4M | $40.4M | ||
| Q1 25 | $29.9M | $54.1M | ||
| Q4 24 | $26.7M | $114.9M | ||
| Q3 24 | $25.1M | $120.2M | ||
| Q2 24 | $25.1M | $117.9M | ||
| Q1 24 | $37.4M | $122.9M |
总债务GYREPDFS
| Q4 25 | — | $67.0M | ||
| Q3 25 | — | $67.6M | ||
| Q2 25 | — | $68.1M | ||
| Q1 25 | — | $68.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GYREPDFS
| Q4 25 | $106.0M | $271.0M | ||
| Q3 25 | $101.9M | $264.4M | ||
| Q2 25 | $92.0M | $257.5M | ||
| Q1 25 | $68.1M | $249.0M | ||
| Q4 24 | $63.3M | $246.0M | ||
| Q3 24 | $63.2M | $240.5M | ||
| Q2 24 | $60.4M | $232.2M | ||
| Q1 24 | $56.6M | $225.4M |
总资产GYREPDFS
| Q4 25 | $166.1M | $418.7M | ||
| Q3 25 | $159.4M | $406.4M | ||
| Q2 25 | $152.6M | $391.1M | ||
| Q1 25 | $129.8M | $390.0M | ||
| Q4 24 | $125.4M | $315.3M | ||
| Q3 24 | $125.2M | $307.4M | ||
| Q2 24 | $120.9M | $298.0M | ||
| Q1 24 | $122.0M | $286.8M |
负债/权益比GYREPDFS
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.6M | $17.3M |
| 自由现金流经营现金流 - 资本支出 | $-5.8M | $7.5M |
| 自由现金流率自由现金流/营收 | -15.5% | 12.1% |
| 资本支出强度资本支出/营收 | 0.4% | 15.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-180.0K | $-8.6M |
8季度趋势，按日历期对齐
经营现金流GYREPDFS
| Q4 25 | $-5.6M | $17.3M | ||
| Q3 25 | $4.7M | $3.3M | ||
| Q2 25 | $2.1M | $-5.2M | ||
| Q1 25 | $-129.0K | $8.6M | ||
| Q4 24 | $-2.8M | $1.6M | ||
| Q3 24 | $1.7M | $9.3M | ||
| Q2 24 | $-5.5M | $684.0K | ||
| Q1 24 | $2.9M | $-1.9M |
自由现金流GYREPDFS
| Q4 25 | $-5.8M | $7.5M | ||
| Q3 25 | $4.0M | $-2.9M | ||
| Q2 25 | $1.8M | $-13.8M | ||
| Q1 25 | $-251.0K | $535.0K | ||
| Q4 24 | $-2.8M | $-4.0M | ||
| Q3 24 | $1.0M | $5.1M | ||
| Q2 24 | $-6.9M | $-4.6M | ||
| Q1 24 | $2.7M | $-3.9M |
自由现金流率GYREPDFS
| Q4 25 | -15.5% | 12.1% | ||
| Q3 25 | 13.1% | -5.1% | ||
| Q2 25 | 6.8% | -26.6% | ||
| Q1 25 | -1.1% | 1.1% | ||
| Q4 24 | -10.1% | -8.0% | ||
| Q3 24 | 4.1% | 11.0% | ||
| Q2 24 | -27.5% | -11.1% | ||
| Q1 24 | 9.8% | -9.4% |
资本支出强度GYREPDFS
| Q4 25 | 0.4% | 15.7% | ||
| Q3 25 | 2.2% | 10.8% | ||
| Q2 25 | 1.0% | 16.5% | ||
| Q1 25 | 0.6% | 17.0% | ||
| Q4 24 | 0.2% | 11.3% | ||
| Q3 24 | 2.7% | 9.0% | ||
| Q2 24 | 5.8% | 12.8% | ||
| Q1 24 | 0.9% | 4.9% |
现金转化率GYREPDFS
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | 2.54× | ||
| Q2 25 | 1.32× | -4.55× | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | -4.85× | 2.98× | ||
| Q3 24 | 0.60× | 4.20× | ||
| Q2 24 | -1.21× | 0.40× | ||
| Q1 24 | 0.29× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GYRE
暂无分部数据
PDFS
| Volumebased | $38.0M | 61% |
| Other | $24.4M | 39% |
